Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide
复制标题

DOI：
10.1002/pros.22890
复制
发表时间：
2014-12-01
期刊：
PROSTATE
影响因子：
2.8
通讯作者：
De Giorgi, Ugo
De Giorgi, Ugo
中科院分区：
医学3区
文献类型：
--
作者：
Conteduca, Vincenza;Burgio, Salvatore Luca;De Giorgi, Ugo

文献摘要

被引文献

相似文献

在这项回顾性研究中，我们评估了嗜铬粒蛋白A （CgA）基线值作为转移性去势抵抗性前列腺癌（CRPC）预后不良的可能因素。方法将35例多西他赛化疗合并恩杂鲁胺治疗后进展的转移性CRPC患者分为3组：血清CgA水平正常时
BACKGROUNDIn this retrospective study, we assessed chromogranin A (CgA) baseline value as a possible factor associated with poor prognosis in metastatic castration-resistant prostate cancer (CRPC).METHODSThirty-five patients with metastatic CRPC progressing after docetaxel chemotherapy treated with enzalutamide are subdivided into three groups: serum CgA level was normal when